THE SAGE GROUP Finds a Significant Number of New Pharmaceuticals in Clinical Trials for Treatment of Peripheral Arterial Disease
ATLANTA, February 13, 2008 -- (BUSINESS WIRE -- According to a report published by THE SAGE GROUP, research activity has intensified on pharmaceutical treatments for peripheral arterial disease (PAD).
“Our analysis found a significant number of new oral therapies in human clinical trials for PAD,” stated Mary L. Yost, author of the report. “Agents are being investigated for the entire spectrum of disease severity including the debilitating walking symptoms of intermittent claudication (IC), limb-threatening critical limb ischemia (CLI) as well as for prevention of ischemic events,” she continued.
“Large Pharma may be awakening to the PAD market opportunity. This marks an important change from 2002, when we began specializing in lower limb disease,” declared Yost.
“Over the past five years, the expansion of the PAD treatment market has been driven almost entirely by the medical device industry with the introduction of innovative endovascular devices,” she explained. “The notable exceptions include Sanofi-Aventis, Bristol-Myers Squibb and several small biotechnology companies,” observed Yost.
According to the report, gene, protein and cell therapies to induce arteriogenesis (angiogenesis) are the hot new areas of research for both IC and CLI. Arteriogenesis, also known as bio-bypass, is the process in which the body grows collateral vessels to bypass an obstruction.
“Several companies including Aldagen, Aastrom Biosciences and Harvest Technologies have developed promising new technologies to separate, concentrate or expand the number of therapeutic cells,” observed Yost.
According to Ms. Yost, “Pharmaceuticals to prevent ischemic events are another area of intense interest.” Anti-ischemic pharmaceuticals include oral anticoagulants, antiplatelets and new oral heparin formulations. For many of these the initial marketing indication is not specifically PAD, rather it is for prevention of ischemic events related to atrial fibrillation, prevention of venous thromboembolism or acute coronary syndrome.
About Peripheral Arterial Disease:
Peripheral Arterial Disease: New Pharmaceuticals to Treat Claudication Symptoms, Prevent Ischemic Events and to Induce Angiogenesis
For additional information: http://www.thesagegroup.us/PadNewPharmacy/index.html
About THE SAGE GROUP
THE SAGE GROUP, a research and consulting company, specializes in vascular disease in the lower limbs.
For additional information visit www.thesagegroup.us.
SOURCE: THE SAGE GROUP
THE SAGE GROUP, Atlanta